Seralite® – FLC* is a rapid lateral flow test for the quantitative measurement of kappa (K) and lambda (λ) immunoglobulin free light chains (FLCs) in serum. The format of this rapid test enables a free light chain service to be offered in all clinical laboratories. This enables the provision of FLC results in ~10 minutes rather than days or weeks. With this simple to use, compact, rapid test, clinicians are able to monitor patients in “real time” supporting faster decision making.
Seralite® – FLC utilises a CE marked and FDA registered lateral flow immunoassay reader, ADxLR5®, where the results are presented on screen in mg/L along with the calculated K/λ ratio.
The assay utilises highly specific, anti-K and anti-λ monoclonal antibodies (mAbs). These monoclonal antibodies display no cross-reactivity to alternate free light chains, bound free chains or other selected human proteins.
The monoclonal antibodies have been comprehensively validated demonstrating that they detect FLCs secreted from both normal and neoplastic plasma cells and have a proven high degree of specificity and sensitivity11**. The assays have been validated using samples from a range of Multiple Myeloma patients at diagnosis, and those being assessed for treatment response and relapse, including Light Chain Multiple Myeloma and Non-Secretory Multiple Myeloma patients.
Seralite® – FLC has proven to provide robust, accurate, and simultaneous measurement of K and λ free light chains in a number of different patient cohorts.
In addition to this Seralite®– FLC has been shown to have:
Speak with a member of the team to learn more about our quantitative rapid lateral flow test, Seralite® – FLC. Please contact us on +44 (0) 1904 406080 or email email@example.com.
Seralite® – FLC Technology
Highly specific, monoclonal antibodies (mAbs) are conjugated to gold particles and incorporated into a simple to use lateral flow device.Read More
Need our help with your lateral flow assay growth strategy? https://t.co/Z4zDmKnw35 https://t.co/UjkKdqwhpU
26 May 2017
© Abingdon Health 2017